<DOC>
	<DOCNO>NCT02057380</DOCNO>
	<brief_summary>The purpose study provide access continue treatment subject participate Astellas sponsor trial investigator feel subject may benefit continued treatment .</brief_summary>
	<brief_title>A Rollover Study Subjects That Have Participated Astellas Sponsored Linsitinib Trial</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subject must currently participate Astellas sponsor linsitinib trial end respect overall study analysis . Subject must meet criterion discontinuation progress current linsitinib study participate . Subject must derive benefit continued treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Linsitinib</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>OSI-906</keyword>
</DOC>